GTC Biotherapeutics to receive patent on protein production via milk

By Lisa Kerner

Erie, Pa., Jan. 9 - GTC Biotherapeutics, Inc. was issued a notice of allowance from the U.S. Patent and Trademark Office covering the production of therapeutic proteins in the milk of transgenic mammals. The application claims include all classes of proteins in all mammals.

The notice of allowance provides GTC with a strong intellectual property position for developing the technology for U.S. markets.

"This broad patent will provide long term protection for GTC's proprietary products in the U.S., including our lead program for ATryn," stated Geoffrey F. Cox, GTC's chairman and chief executive officer, in a news release.

The patent that is expected to be issued will expire in 2021.

GTC's lead program is ATryn, currently under review in Europe for use in patients with a hereditary antithrombin deficiency.

ATryn is in a phase III study for the prevention of thromboembolic events in patients with hereditary antithrombin deficiency undergoing high-risk procedures, such as surgery or childbirth. GTC plans to use the study results to prepare a biologics license application for the U.S. Food and Drug Administration.

Based in Framingham, Mass., GTC Biotherapeutics specializes in the development of therapeutic proteins through transgenic animal technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.